Scientific Advisory Board

Richard Cote, MD,FRSCPath, Chairman -- Founder of Impath Oncology and Professor of Pathology at the University of Southern California.

Anthony Tolcher, MD,FRCP -- Director of Clinical Research, South Texas Accelerated Research Therapeutics in San Antonio.

Franco Muggia, MD – Professor of Medicine at NYU.

Daniel Von Hoff, MD, FACP – Head of Translational Research at the Translational Genomics Research Institute in Phoenix and a founder of Ilex Oncology. Dr. Von Hoff is a past President of the American Association for Cancer Research and is currently Editor-in-Chief of Molecular Cancer Therapeutics and on President Bush’s National Cancer Advisory Board.

Roy Herbst, MD, PhD – Professor of Medicine at MD Anderson Cancer Center in Houston. Dr. Herbst was a key investigator in the clinical development of the EGFR inhibitor, Iressa®.

Charles Schiffer, MD -- Professor of Medicine at Wayne State University. Dr. Schiffer was extensively involved in the clinical development of Gleevec® and is a former Chairman of the Oncology Drug Advisory Committee to the FDA.

Philip Banks, MA -- A biostatistician with 23 years of pharmaceutical and biotechnology industry experience who has participated in the development of seven cancer-related NDAs.

Arul Chinnaiyan, MD, PhD -- Director of Pathology and the Microarray Laboratory at the University of Michigan.

Iressa is a registered trademark of the AstraZeneca group of companies. Gleevec is a registered trademark of Novartis AG.